Impact of breast cancer treatments on sleep disturbances - A systematic review by Costa, AR et al.
lable at ScienceDirect
The Breast xxx (2014) 1e13Contents lists avaiThe Breast
journal homepage: www.elsevier .com/brstReviewImpact of breast cancer treatments on sleep disturbances e A
systematic review
Ana Rute Costa a, b, Filipa Fontes a, b, Susana Pereira b, c, Marta Gonçalves a, b, d,
Ana Azevedo a, b, Nuno Lunet a, b, *
a Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Porto, Portugal
b EPIUnit e Institute of Public Health of the University of Porto (ISPUP), Porto, Portugal
c Department of Neurology, Portuguese Oncology Institute, Porto, Portugal
d Department of Psychiatry and Sleep Medicine Center, CUF Porto Hospital, Porto, Portugala r t i c l e i n f o
Article history:
Received 14 April 2014
Received in revised form
6 August 2014
Accepted 10 September 2014
Available online xxx
Keywords:
Breast neoplasms
Antineoplastic protocols
Sleep
Systematic review* Corresponding author. Departamento de Epidemi
ditiva e Saúde Pública, Faculdade de Medicina da Uni
Prof. Herna^ni Monteiro, 4200-319 Porto, Portugal. Tel.:
222 513 653.
E-mail address: nlunet@med.up.pt (N. Lunet).
http://dx.doi.org/10.1016/j.breast.2014.09.003
0960-9776/© 2014 Elsevier Ltd. All rights reserved.
Please cite this article in press as: Costa AR,
(2014), http://dx.doi.org/10.1016/j.breast.201a b s t r a c t
Sleep disturbances are highly prevalent in women with breast cancer; side effects of cancer treatment
may worsen pre-existing sleep problems and have been pointed to as important determinants of their
incidence. Therefore, we aimed to assess the association between different types of breast cancer
treatment and sleep disturbances, through a systematic review. Medline (using PubMed), CINAHL Plus
with full text, PsycINFO and Cochrane Central Register of Controlled Trials (Central) were searched
from inception to January 2014. Studies that evaluated samples of women with breast cancer, assessed
sleep disturbances with standardized sleep-specific measures, and provided data for different cancer
treatments were eligible. A total of 12 studies met the inclusion criteria. Three studies evaluated
insomnia, five studies assessed sleep quality, two provide data on general sleep disturbances and two
analysed specific sleep parameters. Women submitted to chemotherapy, or radiotherapy, tended to
report higher levels of sleep disturbances. More heterogeneous findings were observed regarding the
effect of surgical treatment and hormonal therapy. However, a sound assessment of the impact of
these treatments was hampered by differences across studies regarding the outcomes assessed,
reporting bias and the fact that most studies did not control for the effect of potential confounders.
The present review highlights the potential relation between breast cancer treatments and sleep
disturbances, particularly of chemotherapy, though more robust evidence is needed for a proper
understanding of these associations.
© 2014 Elsevier Ltd. All rights reserved.Introduction
In the last decades, the trends towards earlier detection of breast
cancer and use of more effective treatments have resulted in higher
incidence and improved survival, along with lower mortality rates
[1e3]. Currently, breast cancer is one of the most frequent, with an
estimated 1.7 million new cases diagnosed in 2012, corresponding
to 25% of all cancers amongwomen [4]. It is also amajor contributor
to the overall number of disability-adjusted life-years (DALYs) lostologia Clínica, Medicina Pre-
versidade do Porto, Alameda
þ351 225 513 652; fax: þ351
et al., Impact of breast cancer
4.09.003due to oncological diseases. In countries with a very high human
development index, the years of life lived with disability account
for over one-third of the age-adjusted DALYs due to breast cancer
[5], which highlights the importance of a comprehensive assess-
ment of its burden.
Sleep disorders are defined as a specific diagnostic of a wide
range of problems characterized by the symptoms of insomnia,
excessive day sleepiness and/or abnormal movements, behaviours,
or sensations [6]. However, different terms related to sleep disor-
ders have been used in the literature, namely sleep disturbances,
insomnia, impaired sleep, sleep patterns and sleep-wake distur-
bances. Since most of the studies in this topic include the evalua-
tion of sleep disorders, global sleep quality or other sleep
characteristics, sleep disturbances have been previously used to
name all sleep-related outcomes [7].treatments on sleep disturbances e A systematic review, The Breast
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estimated that the prevalence of poor sleep in breast cancer pa-
tients range from 20 to 70% [8], depending on the study design and
method of assessment. The proportion of sleep disturbances in this
population is higher than the observed in healthy adults [9,10], and
in other oncological patients [11]. These findings are particularly
relevant since sleep disturbances have a negative impact on the
physiological and psychological functions, including immune
function [12], cognitive impairment [13], depression [14] and fa-
tigue [15], being likewise a strong predictor of different measures of
quality of life in this population [16].
The aetiology of sleep disturbances in breast cancer patients is
multi-factorial; in fact, demographic, environmental and lifestyle
factors, psychological disturbances and comorbid medical disor-
ders have been pointed to as main factors contributing for its
occurrence [8,17,18]. Cancer-related treatments, and their wide
range of side effects, are other important feature frequently asso-
ciated with the occurrence of sleep disturbances [19,20]. In addi-
tion, breast cancer diagnosis and associated treatments, may also
contribute for worsening pre-existing sleep problems [21].
Therefore, we aimed to assess the relation between different
types of breast cancer treatment and sleep disturbances, through a
systematic review of the published evidence.
Methods
We searched Medline (using PubMed), CINAHL Plus with full
text, PsycINFO and Cochrane Central Register of Controlled Trials
(Central), from inception to January 2014, with the following search
expression: (sleep* OR insomnia OR circadian rhythm OR para-
somnia OR hypersomnia OR awakening OR somnolence OR drows-
iness OR wakefulness) AND breast cancer. Searches in CINAHL Plus
with full text were expanded to also include related words.
Observational and experimental studies addressing the effect of
breast cancer treatments (i.e., surgical treatment, chemotherapy,
radiotherapy and hormonal therapy) on sleep disturbances were
eligible. There were no language restrictions.
The exclusion criteria were the following: 1) studies not
involving humans (in vitro or research conducted in animals); 2)
case reports, qualitative research studies, non-systematic reviews
or reviews not addressing the impact of breast cancer treatments
on sleep disturbances, guidelines, conference or meeting abstracts
and theses; 3) studies not involving women with breast cancer; 4)
studies addressing the role of sleep disturbances as a risk factor for
breast cancer; 5) studies not providing data on sleep disturbances
evaluated with standardized sleep-specific measures, such as sleep
questionnaires with established psychometric properties of validity
and reliability, sleep diary, actigraphy or polysomnography; 6)
studies not presenting quantitative data on sleep measures for
different breast cancer treatments.
In addition, we excluded all studies that only evaluated circa-
dian phase markers, including melatonin and core body tempera-
ture, as well as cortisol and other endocrine hormones. This is
because there is insufficient evidence to recommend circadian
phase markers for routine clinical evaluation of circadian rhythm
sleep disorders, as some of these biomarkers are strongly affected
by many other factors that may mask the underlying circadian
signals [22e24].
After the identification of potentially relevant references of
original studies and the exclusion of multiple reports of the same
article, we performed an initial screening of the reference list
based on their titles and abstracts. Further, we conducted a detail
assessment of the full texts and extracted data from those that
met the selection criteria. The reference lists of the studies
selected for inclusion in the systematic review were also screened,Please cite this article in press as: Costa AR, et al., Impact of breast cancer
(2014), http://dx.doi.org/10.1016/j.breast.2014.09.003following the same criteria, to identify other potentially eligible
reports.
From each paper selected for the systematic review, we
collected data regarding the country where the study was con-
ducted, the type of study (clinical trial, cohort, caseecontrol, cross-
sectional), sample characteristics (sample size, age, cancer stage,
time since diagnosis), instruments used to assess sleep distur-
bances, estimates of the association between breast cancer treat-
ments and sleep characteristics, or the necessary information to
compute them, and strategies used to control confounding,
whenever applicable. When multiple reports from the same study
were identified, we extracted data from the report providing the
most detailed and/or valid estimates of the effects of cancer treat-
ments on sleep. Regarding prospective studies with evaluations at
different moments after baseline, only the results corresponding to
the longest follow-up were extracted.
The screening of the reference lists, selection of papers for the
review and data extraction, were accomplished independently by
two researchers (ARC, FF), following predefined criteria. Dis-
crepancies in the assessment performed by the two reviewers
were resolved by consensus or involving a third researcher (NL).
A detailed flowchart of the systematic review is presented as
Fig. 1.
Due to the heterogeneity of the methods used for the
assessment of sleep disturbances, and options for presentation of
results, it was not possible to perform a quantitative synthesis of
the main findings. Therefore, the impact of different breast cancer
treatments on sleep was analysed taking into account the direc-
tion and statistical significance of the associations observed when
comparing each treatment with a reference group (other treat-
ment or absence of that specific type of treatment). The results
were classified as “lower levels of sleep disturbances” when the
breast cancer treatments being assessed were negatively associ-
ated with the occurrence of sleep disturbances, or “higher level of
sleep disturbances” when a positive relation was observed.
Additionally, the results were classified in relation to the corre-
sponding P-values and categorized as follows: <0.050 (statisti-
cally significant); 0.050 and <0.100 (close to statistical
significance); 0.100 (not statistically significant). Whenever
necessary, additional comparisons between treatments were
computed by the authors of the present systematic review, using
the chi-square test for categorical variables, or the t-test for
continuous variables. When the studies evaluated several sleep-
related outcomes, only one result, corresponding to the stron-
gest and/or statistically significant relation between treatment
and sleep disturbances, was considered.
Results
Twelve studies were included in the systematic review
[13,16,25e34], which are described in detail in Appendix 1. Most of
these investigations were conducted in North America (10 in the
United States [16,25e28,30e34] and one in Canada [13]) and one
was from Denmark [29]. The reports were published between 1998
and 2013, but mostly since 2011 (58% of the studies). The median
sample size was 101, ranging between 32 and 3002. Nearly all an-
alyses of the effects of cancer treatment on sleep were cross-
sectional, and longitudinal data was retrieved from one study
[27]. The patients' age ranged between 26 and 89 years, and most
studies included only non-metastatic breast cancer patients; only
two reports included metastatic breast cancer patients [27,30]. In
most studies, data were collected after surgery or after completion
of chemotherapy and/or radiotherapy, with the exception of two
cohort studies, one with a baseline assessment prior to surgery and
with monthly assessments for six months following surgery [27],treatments on sleep disturbances e A systematic review, The Breast
Fig. 1. Systematic review flowchart.
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Table 1
Assessment of risk of bias or confounding of the studies included in the systematic
review.
Studies included in
the systematic review
Assessment of
sleep disturbances
before treatment
Control of
confoundinga
Absence of
reporting
biasb
Caplette-Gingras, 2013 [13]
Desai, 2013 [25]
Starkweather, 2013 [26]
Van Onselen, 2013 [27]
Bower, 2011 [28]
Colagiuri, 2011 [29]
Rand, 2011 [16]
Palesh, 2008 [30]
Bardwell, 2008 [31]
Fortner, 2002 [32]
Stein, 2000 [33]
Berger, 1998 [34]
Low risk of bias or confounding High risk of bias or confounding.
a Control of confounding was considered absent when studies only provided
crude estimates or data to compute them, regarding the relation between treat-
ments and sleep disturbances.
b Quantitative data regarding the impact of breast cancer treatments on sleep
disturbances is presented only when results are statistically significant.
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therapy treatments [34]. Furthermore, the full range of the treat-
ments received by the patients in each of the groups being
compared is not described in most studies.
A summary of the methodological characteristics potentially
associated with bias or confounding is presented in Table 1.
Regarding the timing of assessment of sleep, only one study stated
the evaluation of the participants before surgical treatment [27].
The estimates available from six studies did not control for the
effect of potential confounders [13,25,26,31,32,34]. In four studies,
the impact of breast cancer treatments on sleep disturbances were
not fully reported because the results were not statistically signif-
icant [16,27,32,33].
Concerning the evaluation of sleep disturbances, six different
sleep-specific instruments were used (Table 2), including five types
of subjective assessment [mostly based on the Pittsburgh Sleep
Quality Index (PSQI)], and one type of objective measurement of
sleep (wrist actigraphy). Insomnia was evaluated in three studies
included in this systematic review [13,25,31]. Five studies evaluated
sleep quality [16,28,29,32,33], two assessed general sleep distur-
bances [26,27] and two provided data on specific sleep parameters
[30,34].
The association between breast cancer treatments and sleep
disturbances is summarized in Fig. 2.Surgical treatment
The effect of different surgical treatments on sleep was evalu-
ated in two studies [26,29] (Fig. 2A). Mastectomy and lumpectomy
were associated with lower levels of disturbances when compared
to no surgical treatment (in this case, women were only submitted
to breast biopsy) [26], though not statistically significant. Incon-
sistent findings were observed regarding the effect of mastectomy
when compared with lumpectomy [26,29].Please cite this article in press as: Costa AR, et al., Impact of breast cancer
(2014), http://dx.doi.org/10.1016/j.breast.2014.09.003Chemotherapy
Overall, a tendency for higher levels of sleep disturbance was
observed in women submitted to chemotherapy [27,28,30,31],
although the opposite was observed in three studies (not statis-
tically significant in two) [25,27,29]. When compared with radio-
therapy, chemotherapy was also associated with higher levels of
sleep disturbances [31,33]. Regarding the comparison between
different types of chemotherapy, doxorubicin [34] and FEC
[fluorouracil (5-FU) þ epirubicin þ cyclophosphamide] regimens
may have higher prevalence of sleep disturbances [13]. Women
treated with taxane agents had lower prevalence of sleep distur-
bance than those treated with chemotherapy without taxane
agents [13,25] (Fig. 2B).
Radiotherapy
Breast cancer patients submitted to radiotherapy tended to
report higher levels of sleep disturbances than those not submitted
to this type of treatment [25,29e31]. However, as previously
mentioned, when radiotherapy was compared with chemotherapy,
lower levels of sleep disturbances were observed [31,33] (Fig. 2C).
Hormonal therapy
As shown in Fig. 2D, two studies showed that women submitted
to hormonal therapy were more prone to report sleep disturbances
than those not receiving this type of treatment [29,30]. Although
one study found higher levels of sleep disturbances in women
treated with tamoxifen [31], two other studies reported lower
levels in those women [16,25]. In addition, women taking anas-
trozole presented higher prevalence of insomnia, when compared
with women taking letrozole or exemestane, although these asso-
ciations were not statistically significant [25].
Discussion
This systematic review provides an overview of the best avail-
able evidence on the association between different breast cancer
treatments and sleep disturbances.
Despite the inconsistent results, women submitted to chemo-
therapy, as well as radiotherapy, tended to report higher levels of
sleep disturbances. Less consistent results were observed regarding
the impact of surgical treatments and hormonal therapy. However,
the achievement of most robust findings was hampered by the
heterogeneity of sleep-related outcomes and their assessment, the
partial description of all treatments received by the patients, the
absence of control for confounding observed in most of the studies,
and the presence of reporting bias.
Breast cancer treatments have several associated side effects,
which may contribute to impaired sleep in these patients. The cu-
mulative effect of toxic agents on body functions, the physical
impact of distressing symptoms (including nausea, vomiting,
diarrhoea, urinary frequency or skin reactions related with radio-
therapy), changes in body image and hospitalization, as well as
other comorbid-related conditions (e.g.: pain, fatigue, depression,
anxiety, stress), are frequently reported as the main cause or
aggravating factor for sleep disturbances in this population
[17,18,41]. Another potential risk factor for sleep disturbances
among breast cancer patients is the high proportion of vasomotor
symptomatology, namely hot flashes and night sweats, as a side
effect of chemotherapy-induced ovarian disruption or hormonal
therapy following chemotherapy [42]. Additionally, surgical pro-
cedures are associated with functional impairment, producing pain
and inflammatory responses that can impair sleep and anaestheticstreatments on sleep disturbances e A systematic review, The Breast
Table 2
Description of the methods used for assessment of sleep disturbances in the studies included in the systematic review.
Studies included in
the systematic review
Methods used for the assessment of sleep disturbances Sleep disturbances included in the analysis
PSQI
[35]
GSDS
[36]
ISI
[37]
WHI-IRS
[38]
Daily Sleep
Diary [39]
Actigraphy
[40]
CapletteeGingras, 2013 [13] ✓ ✓ Insomnia: sleep-onset latency, and/or wake after sleep onset,
of at least 30 min occurred at least 3 times per week
(assessed by daily sleep diary); OR subjective complaints of
sleep difficulties, as defined by (a) a score of 3 (much) or 4
(extremely) on the dissatisfaction item of the ISI and
(b) a total ISI score 15.
Desai, 2013 [25] ✓ Insomnia: total ISI score 15.
Starkweather, 2013 [26] ✓ Sleep disturbance: higher total GSDS score.
Van Onselen, 2013 [27] ✓ Sleep disturbance: higher total GSDS score;
Daytime sleepiness: higher GSDS daytime
sleepiness subscale score.
Bower, 2011 [28] ✓ Sleep disturbance: higher PSQI total score.
Colagiuri, 2011 [29] ✓ Sleep difficulty: total PSQI score 5.
Rand, 2011 [16] ✓ Sleep disturbance: higher total PSQI score.
Palesh, 2008 [30] ✓ Duration of time in bed: time between entry
into bed and wake-up time;
Sleep latency: latency to sleep onset from entry into bed;
Sleep efficiency: ratio of time asleep to time in bed;
Wake after sleep onset: total duration of
wake after sleep onset;
Mean Number of Wake Episodes: mean number of
nocturnal wake episodes;
Average Wake Episode Period: average length of
nocturnal wake episodes.
Bardwell, 2008 [31] ✓ Insomnia: total WHI-IRS score 9.
Fortner, 2002 [32] ✓ Sleep latency: higher PSQI sleep latency subscale score;
Sleep disturbance: higher PSQI sleep disturbance subscale score.
Stein, 2000 [33] ✓ Poor sleep quality: higher PSQI score (modified version of PSQI).
Berger, 1998 [34] ✓ Mesor: average value of activity movements over a
specific length of time;
Amplitude: extent of a rhythmic change or range of
activity and rest values over a specified length of time;
Mesor plus amplitude: overall mean activity and
rhythmic fluctuations over the 24-h period approximately
48 h after treatment;
Awakenings at night: number of awakenings per night.
ISI, insomnia severity index; GSDS, general sleep disturbance scale; PSQI, pittsburgh sleep quality index; WHI-IRS, Women's Health Initiative e Insomnia Rating Scale.
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riods [43]. Although we could expect higher levels of sleep distur-
bances among women undergoing mastectomy than those
receiving breast conserving surgery, this was not confirmed in our
study.
For a better understanding of the relation between breast cancer
treatment and sleep disturbances, more prospective studies with
baseline evaluations before treatment are needed. In fact, previous
studies have shown that women with breast cancer frequently
report higher levels of sleep disturbances prior to treatment
[15,44,45], whereas for some patients the onset of insomnia fol-
lowed the breast cancer diagnosis and others reported that cancer
either caused or aggravated their sleep difficulties [21]. In the only
prospective study included in our systematic review that evaluated
sleep disturbances prior to treatments, it was possible to observe a
slight increase followed by a decrease in sleep disturbances,
although the scores remained above the clinically meaningful cut-
off for sleep disturbances [27]. The trajectory of disruptive symp-
toms during treatments also seems to be particularly influenced by
pre-treatment symptoms [46].
Despite the increasing interest observed in the last few years
regarding the impact of breast cancer and their treatments on
sleep disturbances, the assessment of these outcomes also needs
to be improved. In fact, several studies were excluded because
they did not evaluate sleep with standardized sleep-specific
measures. Similar findings were observed in a previousPlease cite this article in press as: Costa AR, et al., Impact of breast cancer
(2014), http://dx.doi.org/10.1016/j.breast.2014.09.003systematic review regarding the methodological approaches of
sleep disturbances and quality of life in adults with cancer: of
the 40 studies included only four used a multi-item sleep spe-
cific instrument [7]. According to the recommendations for a
standard research assessment of sleep or insomnia symptoms, in
epidemiological studies, these characteristics should be evalu-
ated with global sleep and insomnia measures (namely PSQI and
Insomnia Severity Index), sleep diary, actigraphy or poly-
somnography [47]. Thus, we opted to only include those studies
using these types of sleep measures, aiming to guarantee the
quality of sleep assessment. None of the studies included eval-
uated sleep disorders with polysomnography, which is the gold
standard for the assessment of sleep disorders, possibly reflect-
ing the costs and efforts that this measure implies. Additionally,
even when different studies used the same instrument, distinct
sleep-related outcomes were provided in the reports; this hin-
dered the comparison of the impact of breast cancer treatments
by type of sleep disturbance.
Although no formal assessment of selection bias could be
accomplished due to the heterogeneity of data presented in each
study, a total of 12 reports were excluded because they did not
present any quantitative estimates regarding the association be-
tween breast cancer treatment and sleep disturbances [48e59].
With the exception of one study that reported that women taking
tamoxifen had poorer sleep quality than those not submitted to this
treatment [58], all of the other studies did not report the directiontreatments on sleep disturbances e A systematic review, The Breast
Fig. 2. Association between breast cancer treatments and sleep disturbances, namely surgical treatment (A), chemotherapy (B), radiotherapy (C) and hormonal therapy (D).
A.R. Costa et al. / The Breast xxx (2014) 1e136of the results. Also, some of the reports included in this systematic
analysis underreported results without statistical significance,
which may have overestimated our assessment of the impact of
breast cancer treatments on sleep disturbances. Three of the 12
studies included in our review reported data on several sleep-
related outcomes, and we opted to include in the figures summa-
rizing evidence only those corresponding to the strongest and/or
statistically significant relation between treatment and sleep dis-
turbances; although this strategy for data synthesis may also have
contributed to overestimating the relation between treatments and
these side effects, it is more sensitive for the detection of potentially
deleterious effects of treatments.
Another important issue refers to the fact that the associations
between breast cancer treatments and sleep disturbance may be
misestimates due to the lack of control for potential confounding;
in fact, only six of the studies included in the systematic review
presented adjusted estimates. Of the wide range of potential
confounders, for instance, cancer stage, age and menopausal status
appear to be crucial variables. Indeed, treatments options are
dependent of cancer stage and related features (e.g. tumour size)
[60,61], and prevalence of sleep disturbances has been associated
with this factor [21]. Age is also taken into account when deciding
breast cancer treatments [62], and changes in sleep patterns and
higher prevalence of sleep disorders were observed with
increasing age [63]. Additionally, menopausal status may deter-
mine the type of breast cancer treatments, particularly hormonal
therapy [64,65], and postmenopausal women were more likely to
present impaired sleep than pre-menopausal [29,66]. Socio-
economic factors [67,68] and presence of other co-morbidities
[41,62] may also need to be considered in data analysis as po-
tential confounders.Please cite this article in press as: Costa AR, et al., Impact of breast cancer
(2014), http://dx.doi.org/10.1016/j.breast.2014.09.003This systematic review highlights the need for improvements in
methodological procedures in future studies, particularly the
achievement of a consensual definition of sleep disturbances, use of
adequate tools for sleep evaluation, longitudinal analysis of sleep
disturbances, with evaluations preformed prior to treatments, as
well as control for the effect of possible confounders. Our results do
not exclude the hypothesis that breast cancer treatments, particu-
larly chemotherapy, are associated with sleep disturbances, but
more robust evidence is needed for a proper understanding of the
effects of treatment regimens on this outcome with potential
impact in the patients' quality of life.Conflict of interest statement
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association between breast cancer treatments and sleep
disturbances.treatments on sleep disturbances e A systematic review, The Breast
1st author,
Year of
publication (REF)
Study description Subjects characteristics Association between breast cancer
treatments and sleep disturbances
Treatment comparison Main results Control of confounding
Caplette-Gingras,
2013 [13]
Country: Canada
Period of data collection:
2005e2007
Type of study:
Cross-sectional
Aim: “To evaluate
the relationship
between insomnia
and objective ( … )
and subjective (… )
measures of
cognitive functioning”
Study population:
Women treated for a
first diagnosis of Stage-1
through Stage-3
BCA combining surgery,
CTX, and RT in the
past 4 months and having
received HT for
a minimum of 5 week
Sample size: n ¼ 63
”Insomnia ”: n ¼ 47 vs.
“Good sleepers”: n ¼ 16
Age (yr), Range: 30e60
Cancer stage, n (%): Stage I:
14 (22.2), Stage II: 29
(46.0), Stage III: 20 (31.7)
Treatments, n (%):
CTX regimen: FEC: 3 (4.8),
FEC þ Taxane: 18 (28.6),
AC: 24 (38.1), AC þ
Taxane: 18 (28.6)
FEC vs. ACb
(with or without taxane)
Insomnia: 90.5% vs.
66.7%, p ¼ 0.041a
e
Taxane vs. No taxaneb
(FEC or AC)
Insomnia: 69.4% vs.
81.5%, p ¼ 0.277a
e
Desai,
2013 [25]
Country: USA
Period of data collection:
2008e2009
Type of study: Cross-sectional
Aim: “To understand
the prevalence and risk
factors for insomnia in
postmenopausal
BCA patients receiving AIs”
Study population:
Postmenopausal women
with stage 0eIII BCA
receiving a third
generation AI, who had
completed CTX or RT
at least 1 month
prior to enrolment
Sample size: n ¼ 413
“Clinical insomnia”: n ¼ 77 vs.
“No clinical insomnia”: n ¼ 336
Age (yr), Mean: 61.7,
Range: 33e88
Cancer stage, n (%): Stage I:
167 (40.4), Stage II: 195
(47.2), Stage III: 51 (12.4)
Time since diagnosis, n (%):
<2 yr: 132 (32.0), 2e5
yr: 132 (32.0),
5e10 yr: 102 (24.7), 10
yr: 47 (11.4)
Treatments, n (%):
CTX:None: 158 (38.3), CTX but
no Taxane: 105 (25.4), CTX
including Taxane: 150 (36.3);
RT: 288 (69.7);
Prior Tamoxifen: 140 (33.9),
Current HT: Letrozole: 86 (20.8),
Anastrazole: 278 (67.3),
Exemestane: 49 (11.9)
CTX (with or without
taxane) vs. No CTX
Insomnia: 17.6% vs.
20.3%, p ¼ 0.509a
e
CTX þ taxane vs. CTX
wihout taxane
Insomnia: 17.3% vs.
18.1%, p ¼ 0.875a
e
RT vs. No RT Insomnia: 19.8% vs.
16.0%, p ¼ 0.363
e
Prior tamoxifen vs.
No prior tamoxifen
Insomnia: 17.1% vs.
19.4%, p ¼ 0.575
e
Anastrozole (Arimidex) vs.
Letrozole (Femara)
Insomnia: 20.9% vs.
14.0%, p ¼ 0.155a
e
Anastrozole (Arimidex) vs.
Exemestane (Aromasin)
Insomnia: 20.9% vs.
14.3%, p ¼ 0.287a
e
Letrozole (Femara) vs.
Exemestane (Aromasin)
Insomnia: 14.0% vs.
14.3%, p ¼ 0.957a
e
Starkweather,
2013 [26]
Country: USA
Period of data collection:
2003e2006
Type of study: Cross-sectional
Aim: “To examine the
relationships among pro-
and anti-inflammatory
biomarkers and
Age (yr), Mean (SD): 47.7 (7.7),
Range: 27e63
Cancer stage: Stage IeStage III
Time since diagnosis:
Treatments, n (%):
Mastectomy: 21 (65.6),
Lumpectomy: 7 (21.9),
Breast biopsy: 4 (12.5)
Mastectomy vs.
Lumpectomy
Mastectomy vs.
No surgical treatmentc
Lumpectomy vs.
No surgical treatmentc
Sleep disturbance:
Mean (SD): 45.6 (21.1)
vs. 38.1 (10.6), p ¼ 0.38
Sleep disturbance:
Mean (SD): 45.6 (21.1)
vs. 52.8 (16.3), p ¼ 0.527a
Sleep disturbance:
e
e
e
(continued on next page)
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(continued )
1st author,
Year of
publication (REF)
Study description Subjects characteristics Association between breast cancer
treatments and sleep disturbances
Treatment comparison Main results Control of confounding
the presence of pain and
other symptoms
(anxiety, depression, fatigue,
and sleep disorder)
prior to induction of CTX”
Study population: Women
with early-stage BCA at
1 month following fine
needle biopsy or breast
tumour resection (lumpectomy
or mastectomy)
but prior to induction of CTX
Sample size: n¼32
Mean (SD): 38.1 (10.6) vs.
52.8 (16.3), p ¼ 0.100a
Van Onselen,
2013 [27]
Country: USA
Type of study: Cohort
Aim: “To evaluate how
sleep disturbance and
daytime sleepiness
changed from before to
6 months following
surgery and whether certain
characteristics predicted
initial levels and/or the
trajectories of these
parameters“
Study population: Women
who underwent
unilateral BCA surgery
were enrolled prior to
surgery and evaluated
monthly for 6 months
Sample size: n ¼ 396
Age (yr), Mean (SD):
54.9 (11.6)
Cancer stage, n (%):
Stage 0: 73 (18.3),
Stage I:151 (37.9),
Stage IIA, IIB: 141 (35.4),
Stage IIIA, IIIB, IIIC, IV:33 (8.3)
Treatments, n (%):
Breast-conserving: 318 (79.9),
Mastectomy: 80 (20.1), Sentinel
node biopsy: 328 (82.4), Axillary
lymph node dissection: 149 (37.4),
Breast reconstruction at
the time of surgery: 86 (21.6),
Neo-adjuvant CTX: 79 (19.8),
Adjuvant CTX: 133 (33.6),
Adjuvant RT: 224 (56.6)
Adjuvant CTX vs. No-adjuvant CTX
Daytime sleepiness:
Coefficient (SE) from
Linear Modeld: - 0.178
(0.069), p < 0.05f;
Coefficient (SE) from
Quadratic Modele: 0.019
(0.011), p ¼ NS
Sleep disturbance:
Coefficient (SE) from
Linear Modeld: 3.277
(0.874), p < 0.001f;
Coefficient (SE) from
Quadratic Modele:
0.421 (0.144), p < 0.010
Daytime sleepiness
Coefficient(SE) from
Linear Modeld: 0.266
(0.056), p < 0.001;
Coefficient (SE) from
Quadratic Modele:
0.036 (0.009), p < 0.001
Hierarchical linear models
adjusted for education,
employment status, fear
of future diagnostic test,
and adjuvant CTX
Hierarchical linear
models adjusted for
education and depression
symptoms
Hierarchical linear
models adjusted for
education, employment
status, fear of future diagnostic
test, and neo-adjuvant CTX
Bower,
2011 [28]
Country: USA
Type of study: Cross-sectional
Aim: “To characterize
the prevalence and
comorbidity of fatigue,
depressive symptoms,
and sleep disturbance (…);
to determine the contribution of
treatment-related factors to
behavioural symptoms
and inflammation (…)
and to test the hypothesis
that inflammatory
processes would contribute
to these symptoms”
Study population: Women
who completed
Age (yr), Mean: 51.2, Range: 32e66
Cancer stage: Stage 0 e Stage IIIA
Time since diagnosis (months),
Mean: 6.7, Range: 1.7e12.5
Treatments, n (%):
No CTX (n ¼ 53, 51.5%) 
Surgery only: 14 (13.6),
Surgery þ RT: 39 (37.9);
CTX (n ¼ 50, 48.5%) 
Surgery þ CTX: 9 (8.7),
Surgery þ RT þ
CTX: 41 (39.8)
CTX vs. No CTX Sleep disturbance:
Mean (SD): 8.98 (3.62)
vs. 7.19 (4.02), p ¼ 0.01
P-values from analysis of
covariance controlling for age,
time since treatment
completion, and RT
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primary cancer treatment
(surgery, RT, and/or CTX)
within the past 3 months
and not yet started ET
Sample size: n ¼ 103
Colagiuri,
2011 [29]
Country: DNK
Period of data collection:
2001e2004
Type of study:
Cross-sectional analysis
Aim: To investigate “the
prevalence and
predictors of clinically
significant sleep
difficulty in women
with primary BCA”
Study population:
Women included in
a nationwide cohort of
Danish women treated
for primary BCA completed
questionnaires three to
four months post-surgery
Sample size: n ¼ 3002
“No Sleep Difficulty”
(PSQI5):n ¼ 1264
vs. “Sleep Difficulty”
(PSQI5): n ¼ 1738
Age (yr), Mean: 54.4, Range: 26e70
Tumour grade, n (%): 1: 720 (23.8),
2: 1094 (36.2), 3: 636 (21.1),
Nonductal: 570 (18.9)
Treatments, n (%):
Type of surgery:
Mastectomy: 1607 (53.5),
Lumpectomy: 1395 (46.5);
CTX: 1335 (44.5);
HT: 1117 (37.2);
RT: 1300 (43.3)
Lumpectomy vs.
Mastectomy
No CTX vs. CTX
Previous RT vs. No RT
HT vs. No HT
Sleep difficulty:
59.7% vs. 56.6%, p ¼ 0.14
Adjusted OR: 1.22, p ¼ 0.015
Sleep difficulty:
59.1% vs. 56.4%, p ¼ 0.15
Premenopausal women:
Adjusted OR: 1.29, p ¼ 0.16
Menopausal women: NS
Sleep difficulty:
59.8% vs. 56.4%, p ¼ 0.06
Sleep difficulty:
60.2% vs. 56.6%, p ¼ 0.06
Multivariate analysis including age,
marital status, ethnicity, education,
personal income, household wealth,
municipality size, children psychiatric
history, comorbidity, BMI, menopausal
status, alcohol/week, cigarettes/day,
physical activity, physical functioning,
depression and anxiety
e
e
Rand,
2011 [16]
Country: USA
Type of study:
Cross-sectional analysis
Aim: “To evaluate
the relationships among
measures of hot flushes,
perceived hot
flush interference,
sleep disturbance,
and (…) QL”
Study population:
BCA survivors due
to receive AI as initial
adjuvant HT or
following adjuvant
tamoxifen and
completed adjuvant
CTX if indicated
Sample size: n ¼ 395
Age (yr), Mean (SD): 59.3(8.7),
Range: 35-89
Cancer stage: Stage 0eStage III
Treatments: Time since first
surgery for BCA, Mean (SD):
16.4 months (20.4)
Prior tamoxifen vs.
No prior tamoxifen
Sleep disturbance:
b ¼ 0.22, p < 0.05
Structured equation modelling,
including age at surgery, SSRI use,
alcohol use, CTX, ever smoked,
BMI, hot flash severity and frequency,
perceived interference, sleep
disturbance, perceived health
status, anxiety symptoms,
depressive symptoms
Bardwell,
2008 [31]
Country: USA
Type of study:
Cross-sectional analysis
Aim: To assess the
“relative importance
of a wide range of
risk factors for
insomnia” in women
in history of BCA
Age (yr), Mean: 53,
Range: 28-74
Cancer stage, n (%): Stage I:
1033 (39.0), Stage II:
1488 (56.2),
Stage IIIA: 125 (4.7)
Time since diagnosis, n (%):
<1 yr: 615 (23.2), 1e1.9
yr: 836 (31.6),
CTX (with or
without RT) vs. No CTXg
RT (with or
without CTX) vs. No RTg
CTX vs. RTg
Tamoxifen (ever) vs.
No tamoxifen (never)h
Insomnia: 40.0% vs. 38.6%,
p ¼ 0.651a
Insomnia: 39.4% vs. 39.0%,
p ¼ 0.834a
Insomnia: 39.0% vs. 38.4%,
p ¼ 0.828a
Insomnia: 39.9% vs. 37.9%,
p ¼ 0.307a
e
e
e
e
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(continued )
1st author,
Year of
publication (REF)
Study description Subjects characteristics Association between breast cancer
treatments and sleep disturbances
Treatment comparison Main results Control of confounding
Study population:
Women 4 years
post-treatment for Stage I
(1 cm)eIIIA BCA
Sample size: n ¼ 2646
“Insomnia”: n ¼ 1039 vs.
“No insomnia”: n ¼ 1607
2e2.9 yr: 654 (24.7), 3e4
yr: 541 (20.4)
Treatments, n (%): Surgery þ
RT: 518 (19.6); Surgery þ
CTX: 720 (27.2); Surgery þ
CTX þ RT: 1113 (42.1);
Surgery only: 295 (11.1);
Tamoxifen: Current: 1589
(60.1), Former: 191 (7.2),
Never: 866 (32.7)
Palesh,
2008 [30]
Country: USA
Period of data collection:
Type of study: Cross-sectional
Aim: “ To determine
the relationship
between hypothalamic
pituitary axis
(HPA) dysregulation,
vagal functioning,
and sleep problems in women
with metastatic BCA”
Study population:
Women with
metastatic BCA or
recurrent BCA
Sample size: n ¼ 99
Age (yr), Mean (SD): 54.7
(9.6), Range: 36e80
Cancer stage: Metastatic
or recurrent BCA
Treatments, n (%):
CTX: 80 (86),
RT: 75 (81.5), HT: 61 (65.6)
CTX vs. No CTX
RT vs. No RT
HT vs. No HT
Total time in bed:
rho ¼ 0.29, p ¼ 0.006;
b ¼ 0.38, p ¼ 0.001f
Latency: rho ¼ 0.14,
p  0.05;
b ¼ 0.30, p ¼ 0.02
Sleep efficiency:
rho ¼ 0.12, p0.05
WASO: rho ¼ 0.04,
p  0.05
Mean number of wake episodes:
rho ¼ 0, p  0.05
Average wake episode period:
rho ¼ 0.09, p  0.05
Total time in bed:
rho ¼ 0.08, p  0.05
Latency: rho ¼ 0.21,
p < 0.05f
Sleep efficiency:
rho ¼ 0.14, p  0.05
WASO: rho ¼ 0.10, p  0.05
Mean number of wake episodes:
rho ¼ 0.13, p  0.05
Average wake episode period:
rho ¼ 0.09, p  0.05
Total time in bed: rho ¼ 0.16,
p0.05
Latency: rho ¼ 0.20, p  0.05
Sleep efficiency: rho ¼ 0.19,
p  0.05
WASO: rho ¼ 0.24, p ¼ 0.03f
Mean number of wake episodes:
rho ¼ 0.23, p ¼ 0.03
Average wake episode period:
rho ¼ 0.12, p  0.05
Hierarchical regression adjusted for CTX,
pain, depression
e
e
e
e
e
e
e
e
e
e
e
e
e
e
e
e
e
Fortner,
2002 [32]
Country: USA
Period of data collection:
Type of study:
Age (yr), Mean (SD):
51.3 (11.7)
Treatments: Receiving
CTX or RT vs.
No current treatment
Sleep disturbance:
Mean (SD):1.52 (0.64) vs.
1.24 (0.58), p < 0.06 (NS)f
e
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Cross-sectional
Aim: To “describe sleep
in a heterogeneous
sample of breast cancer
patients (…) and
examined the relation
between sleep
disturbance and
health-related QL”
Study population: Breast
cancer patients
presenting to an outpatient
oncology clinic
(19 pre-cancer treatment,
29 receiving
cancer treatment, 23
post-cancer treatment)
Sample size: n ¼ 72
CTX or RT: 41% Sleep latency:
Mean (SD): 1.31 (1.04) vs.
0.93 (0.84), p < 0.10 (NS)
e
Stein,
2000 [33]
Country: USA
Type of study: Cross-sectional
analysis
Aim: “To (…) document
the prevalence
and severity of hot
flashes (…) during
treatment for BCA; [to]
identify medical,
demographic, and
treatment correlates
of hot flashes during
BCA treatment; and [to]
determine the impact of
the hot flashes on (…) QL”
Study population:
Postmenopausal
women with BCA evaluated
during CTX or RT
Sample size: n ¼ 70
Age (yr), Range: 39-81
Cancer stage, n (%):
Stage I: 29 (41.4), Stage II:
34 (48.6), Stage III: 7(10.0)
Treatments, n (%):
Type of Surgery:
Mastectomy: 24 (34.3),
Lumpectomy: 43 (61.4),
Breast Biopsy: 3 (4.3);
CTX: 28 (40); RT: 42(60);
Tamoxifen: 6 (8.6)
CTX vs. RT Sleep Quality: b ¼ 0.11,
p  0.10
Multivariate analysis
including education
Berger,
1998 [34]
Country: USA
Type of study: Cohort
Aim: To describe
“patterns of fatigue
and of activity and rest and
the relationship between
these variables”
Study population:
Newly diagnosed
women with stage I
or II BCA during
the first three adjuvant
Age (yr), Mean (SD):
49.5 (8.64), Range: 33e69
Cancer stage, n: Stage I: 32,
Stage II: 40
Lymph node status:
Positive: 33, Negative: 39
Treatments, n (%):
Type of Surgery: Breast
conservation: 34, Modified
radical mastectomy with
reconstruction: 10, Modified
radical mastectomy without
reconstruction: 28;
Doxorubicin vs.
Non-doxorubicin
Mesor:
Mean (SD): 101.87 (15.48)
vs. 113.73 (13.90), p ¼ 0.024
Amplitude:
Mean (SD):85.86 (19.39)
vs. 95.09 (13.90), p ¼ 0.125
Mesor plus amplitude:
Mean (SD): 183.18 (45.46)
vs. 209.66 (53.76),
p ¼ 0.002f
Awakenings at night:
Mean (SD): 21.77 (14.10)
e
e
e
e
(continued on next page)
A
.R.Costa
et
al./
The
Breast
xxx
(2014)
1
e
13
11
Please
cite
this
article
in
press
as:Costa
A
R,et
al.,Im
pact
ofbreast
cancer
treatm
ents
on
sleep
disturbances
e
A
system
atic
review
,The
Breast
(2014),http://dx.doi.org/10.1016/j.breast.2014.09.003
(c
on
ti
nu
ed
)
1s
t
au
th
or
,
Y
ea
r
of
p
u
bl
ic
at
io
n
(R
EF
)
St
u
d
y
d
es
cr
ip
ti
on
Su
bj
ec
ts
ch
ar
ac
te
ri
st
ic
s
A
ss
oc
ia
ti
on
be
tw
ee
n
br
ea
st
ca
n
ce
r
tr
ea
tm
en
ts
an
d
sl
ee
p
d
is
tu
rb
an
ce
s
Tr
ea
tm
en
t
co
m
p
ar
is
on
M
ai
n
re
su
lt
s
C
on
tr
ol
of
co
n
fo
u
n
d
in
g
ch
em
ot
h
er
ap
y
cy
cl
es
.
Sa
m
p
le
si
ze
:
n
¼
72
CT
X
ad
ju
va
nt
re
gi
m
en
:
C
M
F:
26
,A
C
:2
0,
C
A
F:
26
;
D
ox
or
u
bi
ci
n
:
46
;
N
on
-d
ox
or
u
bi
ci
n
:2
6
vs
.2
2.
13
(1
1.
00
),
p
¼
0.
93
5
A
C
,d
ox
or
u
bi
ci
n
þ
cy
cl
op
h
os
p
h
am
id
e;
A
I,
ar
om
at
as
e
in
h
ib
it
or
s;
B
C
A
,b
re
as
t
ca
n
ce
r;
B
M
I,
bo
d
y
m
as
s
in
d
ex
;
C
A
F,
cy
cl
op
h
os
p
h
am
id
e,
d
ox
or
u
bi
ci
n
,a
n
d
fl
u
or
ou
ra
ci
l;
C
M
F,
cy
cl
op
h
os
p
h
am
id
e,
m
et
h
ot
re
xa
te
,a
n
d
fl
u
or
ou
ra
ci
l;
C
TX
,
ch
em
ot
h
er
ap
y;
D
N
K
,D
en
m
ar
k;
ET
,e
n
d
oc
ri
n
e
th
er
ap
y;
FE
C
,fl
u
or
ou
ra
ci
l(
5-
FU
)
þ
ep
ir
u
bi
ci
n
þ
cy
cl
op
h
os
p
h
am
id
e;
H
T,
h
or
m
on
al
th
er
ap
y;
N
S,
n
ot
st
at
is
ti
ca
lly
si
gn
ifi
ca
n
t;
O
R
,o
d
d
s
ra
ti
o;
PS
Q
I,
Pi
tt
sb
u
rg
h
sl
ee
p
qu
al
it
y
in
d
ex
;Q
L,
qu
al
it
y
of
lif
e;
R
T,
ra
d
io
th
er
ap
y;
SD
,s
ta
n
d
ar
d
d
ev
ia
ti
on
;
SE
,s
ta
n
d
ar
d
er
ro
r;
SS
R
I,
se
le
ct
iv
e
se
ro
to
n
in
re
u
p
ta
ke
in
h
ib
it
or
;
U
SA
,U
n
it
ed
St
at
es
of
A
m
er
ic
a;
W
A
SO
,w
ak
e
af
te
r
sl
ee
p
on
se
t;
yr
,y
ea
rs
.
a
P-
va
lu
es
co
m
p
u
te
d
by
th
e
au
th
or
s
of
th
e
p
re
se
n
t
sy
st
em
at
ic
re
vi
ew
.
b
A
rt
ic
le
in
cl
u
d
ed
d
at
a
co
n
ce
rn
in
g
th
e
im
p
ac
t
on
sl
ee
p
d
is
tu
rb
an
ce
s
of
FE
C
(w
it
h
ou
t
ta
xa
n
e)
,F
EC
þ
Ta
xa
n
e,
A
C
(w
it
h
ou
t
ta
xa
n
e)
,A
C
þ
Ta
xa
n
e.
c
O
ri
gi
n
al
st
u
d
y
co
m
p
ar
ed
m
as
te
ct
om
y
an
d
lu
m
p
ec
to
m
y
w
it
h
br
ea
st
bi
op
sy
.
d
Li
n
ea
r
m
od
el
as
su
m
es
th
at
th
e
p
at
ie
n
ts
’
sl
ee
p
p
ar
am
et
er
le
ve
ls
ch
an
ge
d
at
a
co
n
st
an
t
ra
te
.
e
Q
u
ad
ra
ti
c
m
od
el
as
su
m
es
th
at
th
e
p
at
ie
n
ts
’s
le
ep
p
ar
am
et
er
le
ve
ls
ac
ce
le
ra
te
or
d
ec
el
er
at
e
ov
er
ti
m
e.
R
ec
ei
p
t
of
ad
ju
va
n
t
C
TX
w
as
as
so
ci
at
ed
w
it
h
a
gr
ad
u
al
in
cr
ea
se
in
sl
ee
p
d
is
tu
rb
an
ce
an
d
d
ay
ti
m
e
sl
ee
p
in
es
s
th
at
p
ea
ke
d
at
th
e
th
ir
d
m
on
th
an
d
th
en
d
ec
re
as
ed
fr
om
th
re
e
to
si
x
m
on
th
s
fo
llo
w
in
g
su
rg
er
y.
f
R
es
u
lt
re
p
re
se
n
te
d
in
Fi
g.
2.
g
A
rt
ic
le
al
so
in
cl
u
d
ed
d
at
a
co
n
ce
rn
in
g
th
e
im
p
ac
t
on
sl
ee
p
d
is
tu
rb
an
ce
s
of
su
rg
er
y
þ
R
T,
su
rg
er
y
þ
C
TX
,s
u
rg
er
y
þ
C
TX
þ
R
T
an
d
su
rg
er
y
on
ly
.
h
A
rt
ic
le
al
so
in
cl
u
d
ed
d
at
a
co
n
ce
rn
in
g
th
e
im
p
ac
t
on
sl
ee
p
d
is
tu
rb
an
ce
s
of
cu
rr
en
t,
fo
rm
er
or
n
ev
er
u
se
of
ta
m
ox
if
en
.
A.R. Costa et al. / The Breast xxx (2014) 1e1312
Please cite this article in press as: Costa AR, et al., Impact of breast cancer
(2014), http://dx.doi.org/10.1016/j.breast.2014.09.003References
[1] Amaro J, Severo M, Vilela S, Fonseca S, Fontes F, La Vecchia C, et al. Patterns of
breast cancer mortality trends in Europe. Breast 2013;22(3):244e53.
[2] Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of
screening and adjuvant therapy on mortality from breast cancer. N Engl J Med
2005;353(17):1784e92.
[3] De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al.
Cancer survival in Europe 1999e2007 by country and age: results of
EUROCARE-5 e a population-based study. Lancet Oncol 2014;15(1):23e34.
[4] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLO-
BOCAN 2012 v1.0, Cancer incidence and mortality Worldwide: IARC Cancer-
Base No. 11 [Internet]. Lyon, France: International Agency for Research on
Cancer; 2013. Available from: http://globocan.iarc.fr [accessed on 22.01.14].
[5] Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D,
et al. Global burden of cancer in 2008: a systematic analysis of disability-
adjusted life-years in 12 world regions. Lancet 2012;380(9856):1840e50.
[6] American Academy of Sleep Medicine. The international classification of sleep
disorders: diagnostic and coding manual. 2nd ed. Westchester, IL: American
Academy of Sleep Medicine; 2005.
[7] Berger AM, Sankaranarayanan J, Wanatabe-Galloway S. Current methodo-
logical approaches to the study of sleep disturbances and quality of life in
adults with cancer: a systematic review. Psychooncology 2007;16(5):401e20.
[8] Fiorentino L, Ancoli-Israel S. Insomnia and its treatment in women with breast
cancer. Sleep Med Rev 2006;10(6):419e29.
[9] Carpenter JS, Elam JL, Ridner SH, Carney PH, CherryGJ, CuculluHL. Sleep, fatigue,
and depressive symptoms in breast cancer survivors and matched healthy
women experiencing hot flashes. Oncol Nurs Forum 2004;31(3):591e8.
[10] Carlson LE, Campbell TS, Garland SN, Grossman P. Associations among salivary
cortisol, melatonin, catecholamines, sleep quality and stress in women with
breast cancer and healthy controls. J Behav Med 2007;30(1):45e58.
[11] Savard J, Villa J, Ivers H, Simard S, Morin CM. Prevalence, natural course, and
risk factors of insomnia comorbid with cancer over a 2-month period. J Clin
Oncol 2009;27(31):5233e9.
[12] Savard J, Miller SM, Mills M, O'Leary A, Harding H, Douglas SD, et al. Associ-
ation between subjective sleep quality and depression on immunocompe-
tence in low-income women at risk for cervical cancer. Psychosom Med
1999;61(4):496e507.
[13] Caplette-Gingras A, Savard J, Savard MH, Ivers H. Is insomnia associated with
cognitive impairments in breast cancer patients? Behav Sleep Med
2013;11(4):239e57.
[14] Hsiao F, Chang K, Kuo W, Huang C, Liu Y, Lai Y, et al. A longitudinal study of
cortisol responses, sleep problems, and psychological well-being as the pre-
dictors of changes in depressive symptoms among breast cancer survivors.
Psychoneuroendocrinology 2013;38(3):356e66.
[15] Berger AM, Farr LA, Kuhn BR, Fischer P, Agrawal S. Values of sleep/wake, ac-
tivity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer
chemotherapy. J Pain Symptom Manage 2007;33(4):398e409.
[16] Rand KL, Otte JL, Flockhart D, Hayes D, Storniolo AM, Stearns V, et al. Modeling
hot flushes and quality of life in breast cancer survivors. Climacteric
2011;14(1):171e80.
[17] Lee K, Cho M, Miaskowski C, Dodd M. Impaired sleep and rhythms in persons
with cancer. Sleep Med Rev 2004;8:199e212.
[18] Vena C, Parker K, Cunningham M, Clark J, McMillan S. Sleep-wake distur-
bances in people with cancer part I: an overview of sleep, sleep regulation,
and effects of disease and treatment. Oncol Nurs Forum 2004;31(4):735e46.
[19] Kotronoulas G, Wengstrom Y, Kearney N. A critical review of women's sleep-
wake patterns in the context of neo-/adjuvant chemotherapy for early-stage
breast cancer. Breast 2012;21(2):128e41.
[20] Knobf MT, Sun Y. A longitudinal study of symptoms and self-care activities in
women treated with primary radiotherapy for breast cancer. Cancer Nurs
2005;28(3):210e8.
[21] Savard J, Simard S, Blanchet J, Ivers H, Morin CM. Prevalence, clinical char-
acteristics, and risk factors for insomnia in the context of breast cancer. Sleep
2001;24(5):583e90.
[22] Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora R, Boehlecke B,
et al. Practice parameters for the clinical evaluation and treatment of circadian
rhythm sleep disorders. An American Academy of Sleep Medicine report.
Sleep 2007;30(11):1145e59.
[23] Sack RL, Auckley D, Auger RR, Carskadon MA, Wright KP Jr, Vitiello MV, et al.
Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag
disorders. An American Academy of SleepMedicine review. Sleep 2007;30(11):
1460e83.
[24] Bjorvatn B, Pallesen S. A practical approach to circadian rhythm sleep disor-
ders. Sleep Med Rev 2009;13(1):47e60.
[25] Desai K, Mao JJ, Su I, Demichele A, Li Q, Xie SX, et al. Prevalence and risk
factors for insomnia among breast cancer patients on aromatase inhibitors.
Support Care Cancer 2013;21(1):43e51.
[26] Starkweather AR, Lyon DE, Schubert CM. Pain and inflammation in women
with early-stage breast cancer prior to induction of chemotherapy. Biol Res
Nurs 2013;15(2):234e41.
[27] Van Onselen C, Paul SM, Lee K, Dunn L, Aouizerat BE, West C, et al. Trajectories
of sleep disturbance and daytime sleepiness in women before and after sur-
gery for breast cancer. J Pain Symptom Manage 2013;45(2):244e60.treatments on sleep disturbances e A systematic review, The Breast
A.R. Costa et al. / The Breast xxx (2014) 1e13 13[28] Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and
behavioral symptoms after breast cancer treatment: do fatigue, depression,
and sleep disturbance share a common underlying mechanism? J Clin Oncol
2011;29(26):3517e22.
[29] Colagiuri B, Christensen S, Jensen AB, Price MA, Butow PN, Zachariae R.
Prevalence and predictors of sleep difficulty in a national cohort of women
with primary breast cancer three to four months postsurgery. J Pain Symptom
Manage 2011;42(5):710e20.
[30] Palesh O, Zeitzer JM, Conrad A, Giese-Davis J, Mustian KM, Popek V, et al.
Vagal regulation, cortisol, and sleep disruption in women with metastatic
breast cancer. J Clin Sleep Med 2008;4(5):441e9.
[31] Bardwell WA, Profant J, Casden DR, Dimsdale JE, Ancoli-Israel S, Natarajan L,
et al. The relative importance of specific risk factors for insomnia in women
treated for early-stage breast cancer. Psychooncology 2008;17(1):9e18.
[32] Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH. Sleep and
quality of life in breast cancer patients. J Pain Symptom Manage 2002;24(5):
471e80.
[33] Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G. Impact of hot flashes
on quality of life among postmenopausal women being treated for breast
cancer. J Pain Symptom Manage 2000;19(6):436e45.
[34] Berger AM. Patterns of fatigue and activity and rest during adjuvant breast
cancer chemotherapy. Oncol Nurs Forum 1998;25(1):51e62.
[35] Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh
sleep quality index: a new instrument for psychiatric practice and research.
Psychiatry Res 1989;28(2):193e213.
[36] Lee KA. Self-reported sleep disturbances in employed women. Sleep 1992;15:
493e8.
[37] Bastien CH, Vallieres A, Morin CM. Validation of the insomnia severity index
as an outcome measure for insomnia research. Sleep Med 2001;2(4):
297e307.
[38] Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA.
Validation of the women's health initiative insomnia rating scale in a multi-
center controlled clinical trial. Psychosom Med 2005;67(1):98e104.
[39] Morin CM. Insomnia: psychological assessment and management. New York:
Guildford Press; 1993.
[40] Morgenthaler T, Alessi C, Friedman L, Owens J, Kapur V, Boehlecke B, et al.
Practice parameters for the use of actigraphy in the assessment of sleep and
sleep disorders: an update for 2007. Sleep 2007;30(4):519e29.
[41] Kim HJ, McDermott PA, Barsevick AM. Comparison of groups with different
patterns of symptom cluster intensity across the breast cancer treatment
trajectory. Cancer Nurs 2014;37(2):88e96.
[42] Savard M, Savard J, Quesnel C, Ivers H. The influence of breast cancer treat-
ment on the occurrence of hot flashes. J Pain Symptom Manage 2009;37(4):
687e97.
[43] Berger AM, Parker KP, Young-McCaughan S, Mallory GA, Barsevick AM,
Beck SL, et al. Sleep/wake disturbances in people with cancer and their
caregivers: state of the science. Oncol Nurs Forum 2005;32(6):E98e126.
[44] Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, et al. Fatigue,
sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support
Care Cancer 2006;14(3):201e9.
[45] Denieffe S, Cowman S, Gooney M. Symptoms, clusters and quality of life prior
to surgery for breast cancer. J Clin Nurs 2014;23(17-18):2491e502.
[46] Liu L, Rissling M, Neikrug A, Fiorentino L, Natarajan L, Faierman M, et al. Fa-
tigue and circadian activity rhythms in breast cancer patients before and after
chemotherapy: a controlled study. Fatigue 2013;1(1e2):12e26.
[47] Buysse DJ, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM. Recommen-
dations for a standard research assessment of insomnia. Sleep 2006;29(9):
1155e73.
[48] Liu L, Fiorentino L, Rissling M, Natarajan L, Parker BA, Dimsdale JE, et al.
Decreased health-related quality of life in women with breast cancer is
associated with poor sleep. Behav Sleep Med 2013;11(3):189e206.Please cite this article in press as: Costa AR, et al., Impact of breast cancer
(2014), http://dx.doi.org/10.1016/j.breast.2014.09.003[49] Dhruva A, Paul SM, Cooper BA, Lee K, West C, Aouizerat BE, et al.
A longitudinal study of measures of objective and subjective sleep disturbance
in patients with breast cancer before, during, and after radiation therapy.
J Pain Symptom Manage 2012;44(2):215e28.
[50] Liu L, Mills PJ, Rissling M, Fiorentino L, Natarajan L, Dimsdale JE, et al. Fatigue
and sleep quality are associated with changes in inflammatory markers in
breast cancer patients undergoing chemotherapy. Brain Behav Immun
2012;26(5):706e13.
[51] Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, et al. The
longitudinal relationship between fatigue and sleep in breast cancer patients
undergoing chemotherapy. Sleep 2012;35(2):237e45.
[52] Taylor TR, Huntley ED, Makambi K, Sween J, Adams-Campbell LL, Frederick W,
et al. Understanding sleep disturbances in African-American breast cancer
survivors: a pilot study. Psychooncology 2012;21(8):896e902.
[53] Mosher CE, Duhamel KN. An examination of distress, sleep, and fatigue in
metastatic breast cancer patients. Psychooncology 2012;21(1):100e7.
[54] Rumble ME, Keefe FJ, Edinger JD, Affleck G, Marcom PK, Shaw HS. Contribu-
tion of cancer symptoms, dysfunctional sleep related thoughts, and sleep
inhibitory behaviors to the insomnia process in breast cancer survivors: a
daily process analysis. Sleep 2010;33(11):1501e9.
[55] Dodd MJ, Cho MH, Cooper BA, Miaskowski C. The effect of symptom clusters
on functional status and quality of life in women with breast cancer. Eur J
Oncol Nurs 2010;14(2):101e10.
[56] Savard J, Liu L, Natarajan L, Rissling MB, Neikrug AB, He F, et al. Breast cancer
patients have progressively impaired sleep-wake activity rhythms during
chemotherapy. Sleep 2009;32(9):1155e60.
[57] Aldridge-Gerry A, Zeitzer JM, Palesh OG, Jo B, Nouriani B, Neri E, et al. Psy-
chosocial correlates of sleep quality and architecture in women with meta-
static breast cancer. Sleep Med 2013;14(11):1178e86.
[58] Alvarez J,MeyerFL,GranoffDL, LundyA.TheeffectofEEGbiofeedbackonreducing
postcancer cognitive impairment. Integr Cancer Ther 2013;12(6):475e87.
[59] Rissling MB, Liu L, Natarajan L, He F, Ancoli-Israel S. Relationship of meno-
pausal status and climacteric symptoms to sleep in women undergoing
chemotherapy. Support Care Cancer 2011;19(8):1107e15.
[60] Martin MA, Meyricke R, O'Neill T, Roberts S. Mastectomy or breast conserving
surgery? Factors affecting type of surgical treatment for breast cancerea
classification tree approach. BMC Cancer 2006;6:98.
[61] Kurian A, Lichtensztajn D, Keegan T, Leung R, Shema S, Hershman D, et al. Pat-
terns and predictors of breast cancer chemotherapy use in Kaiser Permanente
Northern California, 2004e2007. Breast Cancer Res Treat 2013;137(1):247e60.
[62] Yancik R, Wesley M, Ries L, Havlik R, Edwards B, Yates J. Effect of age and
comorbidity in postmenopausal breast cancer patients aged 55 years and
older. JAMA 2001;285(7):885e92.
[63] Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 1. Sleep dis-
orders commonly found in older people. CMAJ 2007;176(9):1299e304.
[64] De Vos FY, van Laarhoven HW, Laven JS, Themmen AA, Beex LV, Sweep CG,
et al. Menopausal status and adjuvant hormonal therapy for breast cancer
patients: a practical guideline. Crit Rev Oncol Hematol 2012;84(2):252e60.
[65] Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al.
Progress and promise: highlights of the international expert consensus on the
primary therapy of early breast cancer 2007 Ann Oncol 2007;18(7):1133e44.
[66] Berger AM, Treat Marunda HA, Agrawal S. Influence of menopausal status on
sleep and hot flashes throughout breast cancer adjuvant chemotherapy.
J Obstet Gynecol Neonatal Nurs 2009;38(3):353e66.
[67] Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast
cancer treatment and survival. J Natl Cancer Inst 2002;94(7):490e6.
[68] Anders M, Breckenkamp J, Blettner M, Schlehofer B, Berg-Beckhoff G. Asso-
ciation between socioeconomic factors and sleep quality in an urban
population-based sample in Germany. Eur J Public Health 2013 Nov 26 [Epub
ahead of print].treatments on sleep disturbances e A systematic review, The Breast
